RU2005101874A - Синергетическое взаимодействие абакавира и аловудина - Google Patents
Синергетическое взаимодействие абакавира и аловудина Download PDFInfo
- Publication number
- RU2005101874A RU2005101874A RU2005101874/15A RU2005101874A RU2005101874A RU 2005101874 A RU2005101874 A RU 2005101874A RU 2005101874/15 A RU2005101874/15 A RU 2005101874/15A RU 2005101874 A RU2005101874 A RU 2005101874A RU 2005101874 A RU2005101874 A RU 2005101874A
- Authority
- RU
- Russia
- Prior art keywords
- abacavir
- alovudine
- present
- composition according
- amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
Claims (11)
1. Фармацевтическая композиция, включающая синергетическую комбинацию абакавира и аловудина и фармацевтический носитель для них.
2. Композиция по п.1, где аловудин присутствует в количестве 1-10 мг на стандартную дозу.
3. Композиция по п.2, где аловудин присутствует в количестве 0,5-7,5 мг на стандартную дозу.
4. Композиция по п.3, где аловудин присутствует в количестве 0,5-5 мг на стандартную дозу.
5. Композиция по п.1, где абакавир присутствует в количестве 200-800 мг на стандартную дозу.
6. Композиция по п.5, где абакавир присутствует в количестве 300-500 мг на стандартную дозу.
7. Композиция по п.1, где аловудин и абакавир присутствуют в массовом соотношении, соответствующем ED50 каждого из них.
8. Композиция по п.1, где аловудин и абакавир присутствуют в соотношении 1-10:200-800.
9. Упаковка, предназначенная для пациента, включающая аловудин и/или абакавир и информационный вкладыш, содержащий указания по применению как аловудина, так и абакавира вместе в комбинации.
10. Применение абакавира вместе с аловудином для лечения полирезистентного ВИЧ, где применение включает одновременное, комбинированное или последовательное введение аловудина и абакавира.
11. Применение по п.10, где включающее введение композиции, как определено в любом из пп.1-8, или упаковки для пациента по п.9.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202022-0 | 2002-06-27 | ||
| SE0202022A SE0202022D0 (sv) | 2002-06-27 | 2002-06-27 | Synergistic interaction of abacavir and alovudine |
| EP02024744 | 2002-11-06 | ||
| EP02024744.1 | 2002-11-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005101874A true RU2005101874A (ru) | 2005-06-27 |
| RU2320347C2 RU2320347C2 (ru) | 2008-03-27 |
Family
ID=30001852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005101874/15A RU2320347C2 (ru) | 2002-06-27 | 2003-06-24 | Синергетическое взаимодействие абакавира и аловудина |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060084627A1 (ru) |
| EP (1) | EP1536800B1 (ru) |
| JP (1) | JP2005533870A (ru) |
| KR (1) | KR20050013628A (ru) |
| CN (1) | CN1302779C (ru) |
| AT (1) | ATE314851T1 (ru) |
| AU (1) | AU2003239088B2 (ru) |
| BR (1) | BR0311141A (ru) |
| CA (1) | CA2481890A1 (ru) |
| DE (1) | DE60303131T2 (ru) |
| ES (1) | ES2254941T3 (ru) |
| HK (1) | HK1079981B (ru) |
| IL (1) | IL164921A0 (ru) |
| MX (1) | MXPA04012754A (ru) |
| NO (1) | NO20050445L (ru) |
| NZ (1) | NZ535817A (ru) |
| PL (1) | PL373758A1 (ru) |
| RU (1) | RU2320347C2 (ru) |
| WO (1) | WO2004002433A1 (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1610797A1 (en) * | 2003-03-27 | 2006-01-04 | Boehringer Ingelheim International GmbH | Antiviral combination of nevirapine and a further antiretroviral compound |
| GB0608876D0 (en) | 2006-05-05 | 2006-06-14 | Medivir Ab | Combination therapy |
| CA3003988C (en) * | 2010-01-27 | 2020-01-07 | Viiv Healthcare Company | Combinations for use in the inhibition of hiv-1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8602981D0 (sv) * | 1986-07-04 | 1986-07-04 | Astra Laekemedel Ab | Novel medicinal use |
| US5446029A (en) * | 1986-07-04 | 1995-08-29 | Medivir Ab | Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides |
| GB8719877D0 (en) * | 1987-08-22 | 1987-09-30 | Wellcome Found | Antiviral compounds |
| NZ229453A (en) * | 1988-06-10 | 1991-08-27 | Univ Minnesota & Southern Rese | A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents |
| SE464168B (sv) * | 1989-07-19 | 1991-03-18 | Bo Fredrik Oeberg | Antiviral komposition bestaaende av en 3'-fluoro-2',3'-dideoxynukleosidfoerening och en 2',3'-dideoxynukleosidfoerening (exempelvis azt) |
| MY104575A (en) * | 1989-12-22 | 1994-04-30 | The Wellcome Foundation Ltd | Therapeutic nucleosides. |
| AU5475799A (en) * | 1998-08-10 | 2000-03-06 | Centre National De La Recherche Scientifique | Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis |
| GB9820417D0 (en) * | 1998-09-18 | 1998-11-11 | Glaxo Group Ltd | Antiviral combinations |
| PL198237B1 (pl) * | 1999-01-22 | 2008-06-30 | Univ Emory | Kompozycja farmaceutyczna zawierająca ß-D-D4FC, zastosowanie kompozycji i zastosowanie ß-D-D4FC |
| US6514979B1 (en) * | 1999-03-03 | 2003-02-04 | University Of Maryland Biotechnology Institute | Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor |
| JP2004514652A (ja) * | 2000-06-02 | 2004-05-20 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ−１８およびｉｌ−１８組み合わせを用いるウイルス疾患の治療法 |
-
2003
- 2003-06-24 US US10/519,332 patent/US20060084627A1/en not_active Abandoned
- 2003-06-24 MX MXPA04012754A patent/MXPA04012754A/es active IP Right Grant
- 2003-06-24 WO PCT/SE2003/001100 patent/WO2004002433A1/en active IP Right Grant
- 2003-06-24 ES ES03733801T patent/ES2254941T3/es not_active Expired - Lifetime
- 2003-06-24 KR KR10-2004-7021155A patent/KR20050013628A/ko not_active Application Discontinuation
- 2003-06-24 AT AT03733801T patent/ATE314851T1/de not_active IP Right Cessation
- 2003-06-24 JP JP2004548906A patent/JP2005533870A/ja active Pending
- 2003-06-24 PL PL03373758A patent/PL373758A1/xx not_active Application Discontinuation
- 2003-06-24 CA CA002481890A patent/CA2481890A1/en not_active Abandoned
- 2003-06-24 NZ NZ535817A patent/NZ535817A/en not_active IP Right Cessation
- 2003-06-24 RU RU2005101874/15A patent/RU2320347C2/ru not_active IP Right Cessation
- 2003-06-24 CN CNB038151685A patent/CN1302779C/zh not_active Expired - Fee Related
- 2003-06-24 DE DE60303131T patent/DE60303131T2/de not_active Expired - Fee Related
- 2003-06-24 EP EP03733801A patent/EP1536800B1/en not_active Expired - Lifetime
- 2003-06-24 BR BR0311141-5A patent/BR0311141A/pt not_active IP Right Cessation
- 2003-06-24 AU AU2003239088A patent/AU2003239088B2/en not_active Ceased
-
2004
- 2004-10-28 IL IL16492104A patent/IL164921A0/xx unknown
-
2005
- 2005-01-26 NO NO20050445A patent/NO20050445L/no not_active Application Discontinuation
-
2006
- 2006-01-03 HK HK06100011.9A patent/HK1079981B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE314851T1 (de) | 2006-02-15 |
| PL373758A1 (en) | 2005-09-05 |
| US20060084627A1 (en) | 2006-04-20 |
| DE60303131T2 (de) | 2006-07-20 |
| DE60303131D1 (de) | 2006-03-30 |
| AU2003239088B2 (en) | 2006-11-02 |
| HK1079981A1 (en) | 2006-04-21 |
| MXPA04012754A (es) | 2005-03-23 |
| NZ535817A (en) | 2006-11-30 |
| EP1536800A1 (en) | 2005-06-08 |
| JP2005533870A (ja) | 2005-11-10 |
| NO20050445L (no) | 2005-01-26 |
| CA2481890A1 (en) | 2004-01-08 |
| BR0311141A (pt) | 2005-06-07 |
| HK1079981B (zh) | 2007-10-12 |
| AU2003239088A1 (en) | 2004-01-19 |
| WO2004002433A1 (en) | 2004-01-08 |
| WO2004002433A8 (en) | 2004-05-06 |
| ES2254941T3 (es) | 2006-06-16 |
| RU2320347C2 (ru) | 2008-03-27 |
| EP1536800B1 (en) | 2006-01-04 |
| CN1665509A (zh) | 2005-09-07 |
| KR20050013628A (ko) | 2005-02-04 |
| IL164921A0 (en) | 2005-12-18 |
| CN1302779C (zh) | 2007-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1435240A3 (en) | Solid oral dosage form comprising a combination of methformin and glibenclamide | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| GEP20033131B (en) | Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity | |
| RU2006130623A (ru) | Противоопухолевые сочетания cci-779 и ритаксимаба | |
| AR028504A2 (es) | Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial | |
| NO330947B1 (no) | Anvendelse av farmasoytiske sammensetninger som inneholder okskarbazepin, i fastende tilstand | |
| DE60312523D1 (de) | Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit | |
| ES2074513T3 (es) | Utilizacion de un antagonista opiaceo para la preparacion de una composicion farmaceutica para administracion transdermica y dispositivo para el suministro percutaneo. | |
| JP2010525050A5 (ru) | ||
| RU2010147287A (ru) | Комбинированная композиция | |
| EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
| CA2428160A1 (en) | Compositions for antitumor treatment containing ecteinascidin 743 | |
| PL363313A1 (en) | Deuterated 3-piperidinopropiophenone and medicaments containing said compounds | |
| RU95101385A (ru) | Продукты, содержащие g-csf и tnf связующие протеина | |
| RU2005101874A (ru) | Синергетическое взаимодействие абакавира и аловудина | |
| EA200501223A1 (ru) | Терапевтическая система, содержащая амоксициллин и клавулановую кислоту | |
| RU99119233A (ru) | Фармацевтические композиции, содержащие ибупрофен и домперидон для лечения мигрени | |
| UY26595A1 (es) | Formulaciones de entecavir de dosis bajas y uso | |
| HUP0004461A2 (hu) | Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények | |
| RU2005112720A (ru) | Фармацевтические композиции для улучшенного введения пептидов, происходящих от gp41 вич, и их использование в терапии | |
| ATE462419T1 (de) | Orale pharmazeutische zusammensetzung für weichkapseln mit vinorelbin und behandlungsverfahren | |
| GB0018322D0 (en) | Pharmaceutical compositions | |
| RU2002129356A (ru) | Комбинация лекарственных средств для лечения головной боли, содержащая нестероидное противовоспалительное лекарственное средство | |
| RU2002126216A (ru) | Фармацевтическая композиция для лечения и профилактики фиброза и цирроза печени | |
| AP1435A (en) | A combination kit used in the treatment of malaria. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20080625 |